Clin Osteol 2003; 8(4): 131-134

Effect of transfer factor on biochemical markers of bone turnover and bone mineral density in ovariectomized ratsArticles

J. Rovenský, K. Švík, R. Ištok , M. Stančíková

Transfer factor (TF) is dialyzate of the homogenate of human leucocytes from healthy donors. It contains a mixture of low-molecule biologically acti­ ve substances with molecular weight under 10 kDa. It is used in the treatment of conditions that include disorders of cell-mediated immunity. Based on some theoretical assumptions, as the increase of interferon-Y (IFN-y) in recipients, and some clinical observations, we monitored the effect of TF on biochemical markers of osteoresorption, serum NO and bone mineral density (BMD) in the model of postmenopausal osteoporosis in ovariectomized rats. Our results showed that TF significantly decreases Pyr and Dpyr in urine, and markedly increase bone mineral density and slightly increases BMD of femur. In conclusion, TF inhibited bone resorption and decreased the bone loss in ovariectomized rats.

Keywords: transfer factor, osteoresorption, ovariectomized rats.

Published: December 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rovenský J, Švík K, Ištok R, Stančíková M. Effect of transfer factor on biochemical markers of bone turnover and bone mineral density in ovariectomized rats. Osteologický bulletin. 2003;8(4):131-134.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pekárek J, Čeeh K, Barnet K. Deset let použiváni imunomodulačného připravku Immodin, dřive transfer faetor Sevae v terapii. Sevapharma,a.s., Praha 1997:5-14.
    2. Alvarez-Thull L, Kirkpatriek CH. Profiles of eytokine produetion in reeipi of transfer faetors. Biotherapy 1996;9:55-9. Go to original source...
    3. Hanshaw JB, Dudgeon JA Prevention, treatment, and antiviral therapy. Major Probl Clin Itediatr 1978;17:27^7.
    4. Zielinski CC, Savoini E, Ciotti M, et al. Dialyzable leukoeyte extraet (transfer f tor) in the treatment of superinfeeted fistulating tubereulosis of the bone. Cell Immunol 1984;84:200-5. Go to original source...
    5. Rovenský J, Pekárek J, Rauová Ľ, et al. Imunomodulačné liečebné postupy pri zápalovýeh reumatiekýeh ehorobáeh pomoeou dialyzovaného homogenátu leukoeytov. Sevapharma, a. s., Praha 1997;30:18-24.
    6. Estrada-Parra S, Nagaya A, Serrano E, et al. Comparative study of transfer faetor and aeyelovir in the treatment of herpes zoster. Int J Immunopharmaeol 1998;20:521-35. Go to original source...
    7. Mrázová A, Baša J, Navrátil P, et al. Immodin v dlouhodobé imunomodulaei nemoenýeh s nádorovým onemoenenim ledvin. Immodin v léčbě diseminovanýeh forem renálneho adenokareinómu. Sevapharma, a. s., Praha 1997;30:5-14.
    8. Franehi F, Russo V, Luzi G, et al. Clinieo-immunologieal studies of 32 eases of bone tumors. Minerva Med 1980;71:1815-22.
    9. Takayanagi H, Ogasawara K, Hida S, et al. T-eell-mediated regulation of osteoelastogenesis by signalling eross-talk between RANKL and IFN-gamma: Nature 2000;408:600-5. Go to original source...
    10. Koide M, Maeda H, Roeeisana JL, et al. Cytokine Regulation and the signaling meehanism of osteoelast inhibitory peptide-1 (OIP-1/hSea) to inhibit osteoelast formation. J Bone Miner Res 2003;18:458-65. Go to original source...
    11. Liehý A, Maeek J, Adam M. Determination of hydroxypyridinoline in tissues and urine by high performanee liquid ehromatography. J Chromatogr 1991;563:153-7. Go to original source...
    12. Cortas NK, Waking NW. Determination of inorganie nitrate in serum and urine by a kinetie eadmium-reduetion method. Clin Chem 1990;36:1440-3. Go to original source...
    13. Lowik CW, Nibbering PH, van de Ruit M, et al. Indueible produetion of nitrie oxi­ de in osteoblast-like eells and in fetal mouse bone explants is assoeiated with suppression of osteoclastic bone resorption. J Clin Invest 1994;93:1465-72. Go to original source...
    14. Ralston SH, Todd D, Helfrich M, et al. Human osteoblast-like cells produce n oxide and express inducible nitric oxide synthase. Endocrinology 1994;135:330-6. Go to original source...
    15. O'Shaughnessy MC, Polak JM, Afzal F, et al. Nitric oxide mediates 17(-estradi stimulated human and rodent osteoblast proliferation and differentiation. Biochem Biophys Res Commun 2000;277:604-10. Go to original source...
    16. Zamani G, Pitsillides AA, Rawlinson SC, et al. Mechanical strain stimulates nit oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J Bone Miner Res 1999;14:1123-31. Go to original source...
    17. Hukkanen M, Platts LAM, Lawes T, et al. Effect of nitric oxide donor nitrogl rin on bone mineral density in a rat model of estrogen deficiency-induced osteo­ penia. Bone 2003;32:142-49. Go to original source...
    18. Wimalawansa SJ, ChapaMT, Yallampalli C, et al. Prevention of corticosteroid duced bone loss with nitric oxide donor nitroglycerin in male rats. Bone, 1997; 21:275-80. Go to original source...
    19. Wimalawansa SJ. Nitroglycerin therapy is as efficacious as standard estro placement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 2000;15:2240-4. Go to original source...
    20. Fan X, Roy E, Zhu L, et al. Nitric oxide regulates RANKL and OPG bone marrow stromal cells. Endocrinology 2003,10.1210/en.2003-0726

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.